Boryung said Wednesday that it has signed a sales agreement with Baxter Korea to sell inhalation anesthesia Suprane Solution and blood substitute Plasma Lyte 148 Inj 1,000ml in the domestic market.Suprane (desflurane), the original drug developed by Baxter, is a leading inhalation anesthetic used to
Ildong Pharmaceutical said Wednesday that it has signed an eye drop co-promotion agreement with Hanlim Pharm to enter the OTC (over-the-counter) market in the ophthalmology sector.The items to be co-promoted are three brands of over-the-counter eye drops -- Nazorin, Numaren, and Eyefeel -- which wil
Hyundai Pharm said Wednesday it has received approval from the Ministry of Food and Drug Safety (MFDS) for Niserin Tab 30mg (nicergoline), a brain function enhancer.Nicergoline inhibits alpha-1 adrenergic receptors, resulting in peripheral vasodilation to increase blood circulation in the brain.Nice
SK chemicals said Wednesday that they have launched Nose-R Soft Cap (fexofenadine), a third-generation antihistamine-based drug for allergic rhinitis.Nose-R is available at pharmacies without a prescription and is effective in relieving symptoms of allergic rhinitis caused by pollen and house dust,
Samsung C&T and its subsidiaries Samsung BioLogics and Samsung Bioepis said Tuesday that they have signed a memorandum of understanding for strategic cooperation with Flagship Pioneering in the United States through the Life Science Fund No. 2 (SVIC No. 64 New Technology Investment Fund) established
Celltrion said Wednesday that it has applied to the U.S. Food and Drug Administration (FDA) for securing interchangeability between CT-P17 (adalimumab) and its original drug, AbbVie’s Humira, for treating autoimmune diseases.Celltrion's application for the interchangeability of CT-P17 (Yuflyma in br
On Friday, Samsung Pharm said it has submitted an application to the Ministry of Food and Drug Safety (MFDS) seeking approval to modify the investigational new drug (IND) plan for the phase 3 clinical trial of its Alzheimer's treatment, GV1001.The amended protocol is designed to test the superiority
Celltrion said Monday that it has begun canceling approximately 2.3 million treasury shares to enhance shareholder value.Following the launch of the unified Celltrion, the company aims to bolster its global competitiveness, maintaining shareholder-friendly policies such as outstanding share repurcha
Huons, a Korean healthcare company listed on Kosdaq, said Monday it has received IND approval from the Ministry of Food and Drug Safety for HUC1-394, a treatment for dry eye disease, to conduct a phase 1 clinical trial. HUC1-394 is a peptide-based eye drop for dry eyes. In 2020, Huons licensed-in th
AstraZeneca Korea said that the Ministry of Food and Drug Safety (MFDS) approved Ultomiris (ingredient: ravulizumab) as an adjunct therapy for adults with antibody-positive acetylcholine receptor (AChR) generalized myasthenia gravis (gMG) on Thursday.Ultomiris had been approved for the treatment of
Celltrion said Friday that its Remicade biosimilar, Remsima SC (infliximab), for the treatment of autoimmune diseases, is showing rapid sales growth in Australia.Launched in Australia in July 2021, Remsima SC generated approximately 8 billion won ($6.1 million) in sales in 2022, followed by cumulati
Korea recorded a trade deficit due to the global economic downturn in 2023, despite achieving the highest export volume in December.Notably, the biotech and healthcare industry, one of the five promising sectors, has experienced a continuous deficit for 16 months since July 2022.Despite an increase
GC Cell said that BioCentriq, its U.S. affiliate focused on cell and gene therapy (CGT) contract development and manufacturing organization (CDMO), successfully raised a total of $29.2 million in a Series A funding.BioCentriq was acquired by GC Cell and Green Cross Holdings in 2022. The company, bas
Dong-A ST said it has signed a licensing agreement with SK biopharmaceuticals for the epilepsy drug cenobamate in 30 countries, including Korea, Southeast and Southwest Asia, Russia, Australia, New Zealand, and Turkey.The deal excludes the U.S. as cenobamate has been commercially available in the U.
The recent regulatory approval of bispecific antibodies Lunsumio (mosunetuzumab) and Columvi (glofitamab) in Korea has opened new treatment options for patients with relapsed lymphoma. Attention is particularly on a possible rivalry between Roche’s Columvi and Novartis’ CAR-T therapy Kymriah (tisage
Korean pharmaceutical and biotech firms are set to participate in the upcoming J.P. Morgan Healthcare Conference, the world's largest healthcare conference known for capturing the interest of institutional investors. The event is scheduled to commence in San Francisco, the U.S., from Jan. 8-11.The c
Dong-A ST said Wednesday that it has launched a combination drug, Sugatree Tab, for type 2 diabetes.Sugatree combines evogliptin 5 mg, the main component of Suganon, a dipeptidyl peptidase 4 (DPP-4) inhibitor, with dapagliflozin 10 mg, sodium-glucose transport protein 2 (SGLT-2) inhibitor, and 1,000
Pfizer's second-generation targeted therapy for chronic myeloid leukemia, Bosulif (bosutinib), has been newly registered with the health insurance program this month.A patient group welcomed the news and called for expanding its reimbursement to treat children.Last Dec. 22, the Ministry of Health an
Medytox, a Korean botulinum toxin (BTX) maker, said it has established a U.S. subsidiary Luvantas to advance into the global market with MT10109L, its non-animal-derived liquid BTX formulation.The company had submitted a biologics license application (BLA) for MT10109L to the FDA in late December. T
MedPacto, a Korean immunotherapy developer, said Wednesday that the U.S. FDA has approved a phase 2b/3 investigational new drug (IND) plan for the combination of its immunotherapy, vactosertib, and MSD’s Keytruda (pembrolizumab), in patients with metastatic colorectal cancer.For phase 2b/3 study, Me